TADALAFIL (CIALIS™) FOR MEN WITH ERECTILE DYSFUNCTION

Tadalafil is an inhibitor of phosphodiesterase type 5, and is currently undergoing regulatory review in the US and in Europe. Its chemical structure is significantly different from sildenafil, and in vitro studies confirm significant potency for PDE5 inhibition, with little activity against most of the other isoforms of the enzyme including PDE6, which is the isoform of the enzyme found within the retina. The half‐life of tadalafil is 17.5 hours and clinical studies suggest significant activity 24 hours post‐dosing. As with sildenafil, efficacy depends upon a normal sexual stimulus, and the drug can taken be as required. Tadalafil is effective in the treatment of men with erectile dysfunction, and it appears to have a relatively mild side‐effect profile, with no visual side‐effects noted.

• Publication year

  2002

• Venue

  International journal of clinical practice

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1742-1241.2002.tb11260.xPMID 12074215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers

  2002cited by this paper
• The role of nitric oxide in penile erection

  2001cited by this paper
• Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction

  2001cited by this paper
• On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction

  2001cited by this paper
• Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’

  2000cited by this paper
• Erectile dysfunction.

  2000cited by this paper
• Sildenafil: a review of its use in erectile dysfunction.

  1999cited by this paper
• Treatment of erectile dysfunction in men with diabetes.

  1999cited by this paper
• Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

  1998cited by this paper
• Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

  1997cited by this paper
• The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.

  1996cited by this paper
• Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

  1994cited by this paper

• Nanomolar level detection of phosphodiesterase 5 inhibitor drug tadalafil based on halide perovskite@HNTs nanocomposite electrode

  2024cites this paper
• TO STUDY THE EFFECT OF TADALAFIL IN IMPROVING URODYNAMIC PARAMETERS IN SPINAL CORD INJURY PATIENTS: A RANDOMIZED CONTROLLED TRIAL

  2024cites this paper
• Management of Persistent Erectile Dysfunction after COVID-19 Infection: An 18-Month Follow-Up Case Report

  2023cites this paper
• Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of Plant Pathogenic Fungi

  2021cites this paper
• Efectos del tadalafilo en el deseo sexual y la excitación/lubricación en mujeres postmenopáusicas

  2021cites this paper
• Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions

  2021cites this paper
• Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects.

  2020cites this paper
• Pharmacology of Male Sexual Function

  2020cites this paper
• Nutraceutical induction and mimicry of heme oxygenase activity as a strategy for controlling excitotoxicity in brain trauma and ischemic stroke: focus on oxidative stress

  2020cites this paper
• An update on the drug safety of treating erectile dysfunction

  2019cites this paper
• Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors

  2017influential citation
• The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

  2016cites this paper
• Drugs for Treatment of Erectile Dysfunction

  2016cites this paper
• Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia

  2016cites this paper
• Erectile dysfunction drugs and oxidative stress in the liver of male rats

  2015cites this paper
• Current use of phosphodiesterase inhibitors in urology.

  2015cites this paper
• Erectile Dysfunction Drugs and Protein Expression of Glutathione S-transferase and Glutathione Peroxidase in the Liver of Male Rats

  2015cites this paper
• Sexual dysfunction in patients with spinal cord lesions.

  2015cites this paper
• Ürolojide fosfodiesteraz inhibitörlerinin güncel kullanimi

  2015cites this paper
• Pathophysiology of erectile dysfunction.

  2015cites this paper
• Case Report of Tadalafil-Induced Central Serous Chorioretinopathy

  2014cites this paper
• Regional cerebral blood flow following single‐dose and continuous‐dose tadalafil after stroke

  2014cites this paper
• Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms

  2014cites this paper
• Erectile dysfunction medication induced-changes in plasma levels of homocysteine and antioxidant enzyme activities as risk factors for cardiovascular disease

  2013cites this paper
• Phosphodiesterase inhibitors in clinical urology

  2013cites this paper
• Chapter 40 – Retinitis Pigmentosa and Allied Disorders

  2013cites this paper
• Improvement in symptoms of peripheral arterial disease with sildenafil therapy

  2013cites this paper
• Pharmacological Potential of PDE5 Inhibitors for the Treatment of Cystic Fibrosis

  2012cites this paper
• PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis

  2012cites this paper
• Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.

  2012cites this paper
• Pharmacological Potential of PDE 5 Inhibitors for the Treatment of Cystic Fibrosis

  2012cites this paper
• Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.

  2012cites this paper
• The recent phosphodiesterase type 5 inhibitors: an update

  2012cites this paper
• Erektile Dysfunktion (ED): Diagnostik und Therapie

  2012cites this paper
• Tadalafil Once-Daily: Patient and Partner Perspective in the Management of Erectile Dysfunction

  2011cites this paper
• Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

  2011cites this paper
• Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.

  2011cites this paper
• Future prospects in the treatment of erectile dysfunction: focus on avanafil

  2011cites this paper
• A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

  2010cites this paper
• Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.

  2010cites this paper
• Efectividad y satisfacción con el tratamiento en pacientes con disfunción eréctil en España: Estudio EDOS

  2010cites this paper
• cGMP is required for seed germination in Arabidopsis thaliana.

  2010cites this paper
• [Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study].

  2010cites this paper
• THE INDIAN JOURNAL OF CHEST DISEASES AND ALLIED SCIENCES

  2009cites this paper
• Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

  2009cites this paper
• Assessment and treatment options for erectile dysfunction

  2008cites this paper
• Grundlagen der Phosphodiesterase-5- (PDE5-)Inhibitoren

  2008cites this paper
• Tablette, Pumpe oder Spritze?

  2008cites this paper
• The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy

  2007cites this paper
• Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury.

  2007cites this paper
• Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve‐induced release of nitric oxide from the rabbit corpus cavernosum

  2007cites this paper
• Optimizing the Response of Phosphodiesterase-5 Inhibitors in the Treatment of Erectile Dysfunction

  2007cites this paper
• Design of second generation phosphodiesterase 5 inhibitors.

  2007cites this paper
• Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial.

  2007cites this paper
• Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase

  2007cites this paper
• Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction

  2007cites this paper
• Nonurologic applications of phosphodiesterase type 5 inhibitors

  2007cites this paper
• The future of the oral pharmacotherapy of male erectile dysfunction: things to come

  2007cites this paper
• Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.

  2006cites this paper
• Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.

  2006cites this paper
• Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.

  2006cites this paper
• A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.

  2006cites this paper
• Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta

  2006cites this paper
• Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.

  2006cites this paper
• Synergistic Effects of Atorvastatin and Sildenafil in Cardioprotection—Role of NO

  2006cites this paper
• Tadalafil: a clinical update

  2005cites this paper
• Cyclic nucleotide signaling in cavernous smooth muscle.

  2005cites this paper
• The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

  2005cites this paper
• Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part II)

  2005cites this paper
• Safety and Tolerability of Oral Erectile Dysfunction Treatments in the Elderly

  2005cites this paper
• New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.

  2005cites this paper
• Physiology of penile erection and pathophysiology of erectile dysfunction.

  2005cites this paper
• Therapie der erektilen Dysfunktion

  2005cites this paper
• Recurrent epistaxis after treatment with tadalafil (Cialis)

  2005influential citation
• ORIGINAL RESEARCH—BASIC SCIENCEORIGINAL RESEARCH—BASIC SCIENCE: Cyclic Nucleotide Signaling in Cavernous Smooth Muscle

  2005cites this paper
• Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I)

  2005influential citation
• Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries—immunohistochemical distribution and functional significance

  2005cites this paper
• Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.

  2005cites this paper
• Diagnostik und Therapie der erektilen Dysfunktion beim Herzpatienten

  2005cites this paper
• Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

  2004cites this paper
• Specific aspects of erectile dysfunction in endocrinology

  2004cites this paper
• Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients

  2004cites this paper
• Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports

  2004cites this paper
• Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone

  2004cites this paper
• Update on oral treatments for male erectile dysfunction

  2004cites this paper
• Sensomotorische und autonome Neuropathie: Neue Therapieoptionen, die Sie kennen sollten

  2004cites this paper
• Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction.

  2004cites this paper
• Cyclic nucleotide signaling in vascular and cavernous smooth muscle: aging-related changes

  2004cites this paper
• Nerve-induced release of nitric oxide in gastrointestinal and erectile tissue

  2004cites this paper
• The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits

  2004cites this paper
• NERVE-INDUCED RELEASE OF NITRIC OXIDE IN GASTROINTESTINAL AND ERECTILE TISSUE

  2004cites this paper
• Understanding erectile dysfunction medication preference studies

  2004cites this paper
• Tadalafil: A Comprehensive Update

  2004cites this paper
• Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil

  2004cites this paper
• Disfunción eréctil, abordaje y tratamiento integral desde atención primaria

  2003cites this paper
• TREATING ERECTILE DYSFUNCTION

  2003cites this paper
• Tadalafil in the treatment of erectile dysfunction

  2003cites this paper
• PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

  2003cites this paper
• Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction.

  2003cites this paper
• Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.

  2003cites this paper